Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Both weekend warriors and steady exercisers had a significantly lower risk of premature death compared to inactive peoples, ...

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing ...

Hims & Hers stirred the weight-loss waters by announcing it now offers prescriptions for Zepbound, Eli Lilly’s premium GLP-1 ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Its latest results show that 35% of Americans could not access quality health care if they need it. Rates were even higher ...